From the Media
RANBAXY ENTERS VACCINES ARENA WITH THE ACQUISITION OF PRODUCT RIGHTS AND MANUFACTURING FACILITY FROM BIOVEL
India’s first medical technology park opens in Tamil Nadu
Bangladesh plans to regulate animal feed production to stop antibiotics from getting into the food chains
Toilet seat triggers skin infections among kids
Simple steps can reduce bloodstream infections in infants
A blog of Indian Initiative for Management of Antibiotic Resistance (IIMAR) managed by Dr. A. J. Tamhankar
Tuesday, January 26, 2010
Thursday, January 21, 2010
Indo - Asian Antibiotic News 2010 - by Dr.A.J.Tamhankar
`Bacteria are big thinkers` say American scientists (Times of India-21 jan 2010) German scientists develop fast-acting germ killer (Times of India-21 jan 2010)
"Bangladesh Pharmaceuticals & Healthcare Report Q1 2010", published
Yesudas seeks price control on life-saving drugs including antibiotics.
Quacks rampant in Rawalpindi and prescribing antibiotics
About half- 40-45 percent drugs sold in Pakistan are spurious
"Bangladesh Pharmaceuticals & Healthcare Report Q1 2010", published
Yesudas seeks price control on life-saving drugs including antibiotics.
Quacks rampant in Rawalpindi and prescribing antibiotics
About half- 40-45 percent drugs sold in Pakistan are spurious
Saturday, January 16, 2010
Indo - Asian Antibiotic News 2010 - by Dr.A.J.Tamhankar
No vaccine or antiviral treatment is currently available for hand, foot, and mouth disease (HFMD), and it has become a very serious problem in Asia in recent years. The disease is highly contagious and a growing number of HFMD cases have been reported in parts of Asia, including Mainland China, Hong Kong, Singapore, Korea, and Taiwan. Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has announced that it has filed the application with China's State Food and Drug Administration (SFDA) to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand, foot, and mouth disease (HFMD).
Monday, January 4, 2010
Indo - Asian Antibiotic News 2009 - Dr.A.J.Tamhankar
RANBAXY LAUNCHES `LULIFIN (LULICONAZOLE)` IN INDIA
Lulifin is a topical imidazole and is indicated for Cutaneous mycoses caused by Tinea pedis, Tinea corporis, Tinea cruris. Currently, topical imidazoles and allylamines are used for the treatment of Cutaneous mycoses with disadvantages like long duration of therapy, which leads to poor compliance and a high relapse rate. Clinical trials conducted in Japan and by Ranbaxy, in India, confirm the at par efficacy with other topical imidazoles but with the added advantage of shorter therapy duration and once a day application. This greatly improves patient compliance with significantly better outcomes.
Lulifin is a topical imidazole and is indicated for Cutaneous mycoses caused by Tinea pedis, Tinea corporis, Tinea cruris. Currently, topical imidazoles and allylamines are used for the treatment of Cutaneous mycoses with disadvantages like long duration of therapy, which leads to poor compliance and a high relapse rate. Clinical trials conducted in Japan and by Ranbaxy, in India, confirm the at par efficacy with other topical imidazoles but with the added advantage of shorter therapy duration and once a day application. This greatly improves patient compliance with significantly better outcomes.